Table 3. Analysis of clinical variables associated with treatment response of EGFR TKI.
| Predictor | Univariate | Multivariate | ||
|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | |
| Age, yr | ||||
| ≥60 vs. <60 | 2.04 (0.72–5.75) | 0.180 | 2.11 (0.71–6.27) | 0.177 |
| Sex | ||||
| Male vs. Female | 3.10 (1.07–8.94) | 0.037 | 1.83 (0.33–10.18) | 0.492 |
| Smoking history | ||||
| Ever vs. Never | 3.10 (1.05–9.19) | 0.041 | 2.00 (0.34–11.74) | 0.443 |
| Stage at EGFR TKIs use | ||||
| IV vs. IIIb | 1.46 (0.09–24.43) | 0.792 | - | - |
| ECOG PS at TKI treatment | ||||
| ≥2 vs. 0–1 | 2.45 (0.84–7.11) | 0.100 | - | - |
| TKIs | ||||
| Gefitinib vs. Erlotinib | 1.25 (0.45–3.49) | 0.670 | - | - |
| Line | ||||
| 3rd-line and above vs. 1st- or 2nd-line | 0.72 (0.27–1.95) | 0.523 | - | - |
| Extrathoracic metastasis | 0.63 (0.19–2.05) | 0.438 | - | - |
| Brain | 1.36 (0.43–4.33) | 0.607 | - | - |
| Bone | 1.23 (0.45–3.37) | 0.690 | - | - |
| No. of extrathoracic metastasis sites | ||||
| ≥3 vs. 1–2 | 1.43 (0.24–8.41) | 0.693 | - | - |
| SISH | ||||
| Negative vs. Positive | 2.25 (0.32–15.76) | 0.414 | - | - |
EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; OR: odds ratio; CI: confidence interval; ECOG PS: Eastern Cooperative Oncology Group performance status; SISH: silver in situ hybridization.